L’Oréal and Galderma’s 2026 data shows that growth in prestige beauty is driven not by formulas or luxury marketing, but by licensed intermediaries like dermatologists, prescribers, and salon professionals. While luxury skincare recovers slowly, prescription and professional categories are surging—a trend amplified by GLP-1 treatments and supply chain strength in Korean pharma and manufacturers.

Estée Lauder wrote USD 375 million off Dr.Jart+ in fiscal 2025, then ran a sale process for the brand, took bids, and decided in July 2026 to keep it and shrink the team instead. The company's fiscal 2026 results, published on 19 August 2026, name Dr.Jart+ in exactly two places. This is the clearest public record of what happens to a Korean brand after the exit everyone treats as the finish line.